Centessa Pharmaceuticals — Investor Presentation (April 2024)
37 slides from Centessa Pharmaceuticals's investor presentation, Apr 22, 2024
Slide 1: Corporate Overview
APRIL 22, 2024 Corporate Overview
Slide 2: Disclaimer and Forward Looking Statements
2 DISCLAIMER AND FORWARD LOOKING STATEMENTS 2 This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential
Slide 3: Discovering and developing medicines that are transformational for patients
Discovering and developing medicines that are transformational for patients 3 Multiple potential blockbuster assets Ongoing momentum in 2024 with clinical milestones anticipated across our most advanced programs Strong balance sheet OUR MISSION
Slide 4: Our Most Advanced Potential First-in-Class/Best-in-Class Medicines for Patients
4 Our Most Advanced Potential First-in-Class/Best-in-Class Medicines for Patients ASSET DISEASE MECHANISM PRE- CLINICAL PHASE 1 PHASE 2 REGISTRATIONAL SerpinPC Hemophilia B Activated Protein C Inhibitor ORX750 Narcolepsy Orexin Receptor-2 (OX2R) Agonist LB101 Solid Tumors PD-L1xCD47 LockBody®
Slide 5: 2024 Driving Momentum
5 2024 Driving Momentum ANTICIPATED MILESTONES LOCKBODY TECHNOLOGY PLATFORM LB101 Phase 1/2 study ongoing OREXIN AGONIST PROGRAM ORX750 Clinical PoC data in healthy volunteers expected in 2H of 2024 HEMOPHILIA PROGRAM SerpinPC Registrational study interim analysis expected in 2024
Slide 6: Hemophilia Program
6 Hemophilia Program LockBody Technology Platform Orexin Agonist Program
Slide 7: Hemophilia B: Large Growing Market with Unmet Need
7 Hemophilia B: Large Growing Market with Unmet Need 1. Evaluate Pharma Analyst Consensus for 2023. 2. In Canada, a subcutaneous option is available for hemophilia B with inhibitors. A safe, subcutaneous and effective treatment has the potential to transform care for hemophilia B No subcutaneous tre
Slide 8: SerpinPC potential first-in-class subcutaneous therapy with differentiated safety profile
8 SerpinPC has the potential to be a first-in-class subcutaneous therapy with a differentiated safety profile for people with hemophilia B1 Novel mechanism of action Showed significant reduction in bleeding1 Shown to have a favorable safety and well tolerated profile to date; No thrombosis observed
Slide 9: SerpinPC: Novel Approach
SerpinPC Designed to reduce levels of circulating activated protein C (APC) SerpinPC: Novel Approach Designed to Prevent and Reduce Bleeding 9 P ro th ro m b in as e
Slide 10: Phase 1/2a Ongoing Study of SerpinPC in Hemophilia
PK=pharmacokinetics; SAD=single ascending dose; MAD=multiple ascending dose; OLE=open-label extension. Reference: ClinicalTrials.gov. NCT04073498. Accessed January 18, 2024. AP-0101 (NCT04073498) | An adaptive, first-in-human study to investigate the safety, tolerability, efficacy, and pharmacokinet
Slide 11: Phase 2a Part 5: SerpinPC Achieved a 96% Reduction in Median All-Bleeds ABR
11 Phase 2a Part 5: SerpinPC Achieved a 96% Reduction in Median All-Bleeds ABR 1 AP-0101 Part 5 all bleed ABR at 1.2 mg/kg Q2W (n=20) 1 60 40 20 0 20 40 60 Baseline Medians Part 5 HemA HemB 1.035.6 ABR In Part 5, SerpinPC reduced median all-bleeds ABR to 1.0, a 96% reduction from prospective baselin
Slide 12: SerpinPC Shown to Have Favorable Safety and Tolerability Profile to Date
SerpinPC Shown to Have Favorable Safety and Tolerability Profile to Date Source: Phase 2a study data of SerpinPC. Part 5: Blood (2023) 142 (Supplement 1): 2619 . *Two SAEs occurred and were considered unrelated to study drug: (1) traumatic fracture of femur (led to discontinuation) (2) traumatic epi
Slide 13: SerpinPC's Potential for Differentiated Safety Profile
13 1. Error bars represent 95% confidence interval. Note: Values from three instances of trauma, cancer and infection determined to represent explained D-dimer elevation and omitted from calculation (Subject 200-012 traumatic hip bleed, week 68 and 72; Subject 300-041 rectosigmoid cancer, Weeks 60-9
Slide 14: SerpinPC Ongoing Global Registrational Studies for Hemophilia B
SerpinPC Ongoing Global Registrational Studies for Hemophilia B Hemophilia B with inhibitors (n ≥ 12) Hemophilia B without inhibitors (n = 120) 73 SITES 18 COUNTRIESPrimary Endpoint: ABR at 24 weeks ABR is annualized bleeding rate. Primary endpoint is the rate of treated bleeds (expressed as ABR) du
Slide 15: SerpinPC Granted Fast Track and Orphan Drug Designations
15 SerpinPC Ongoing Global Registrational Studies for Hemophilia B Granted Fast Track designation by the FDA in May 2023 Granted Orphan Drug Designation by the FDA in Sept. 2022
Slide 16: Potential Multi-Billion-Dollar Market Opportunities
16 Hemophilia B without inhibitors Hemophilia A Hemophilia B with inhibitors Rare bleeding disorders Potential Multi-Billion-Dollar Market Opportunities significant expansion opportunities SerpinPC Evaluate Pharma Analyst Consensus for 2023.
Slide 17: Orexin Agonist Program
17 Hemophilia Program LockBody Technology Platform Orexin Agonist Program
Slide 18: Orexin agonists have the potential to transform standard of care for sleep-wake disorders
Orexin agonists have the potential to transform standard of care for individuals with sleep-wake disorders 18
Slide 19: ORX750 Mechanism of Action
ORX750 Highly potent, selective orexin receptor type 2 (OX2R) agonist Designed to restore orexinergic neurotransmission MOA 19
Slide 20: ORX750 a Potential Best-in-Class Oral OX2R Agonist
20 ORX750 a Potential Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders Preclinical data support potential expansion into broader sleep-wake disorders, including narcolepsy type 2 and idiopathic hypersomnia 1 Investigational New Drug (IND) application ope
Slide 21: ORX750 Showed High In Vitro Potency at OX2R and Selectivity vs. OX1R
-12 -10 -8 -6 0 25 50 75 100 Log concentration (M) Activation (% total) ORX750 Showed High In Vitro Potency at OX2R and Selectivity vs. OX1R Activation pattern was indistinguishable from OXA with lack of biased agonism1 No significant differences in OX2R potency were observed across species2 No sign
Slide 22: ORX750 Increased Wakefulness and Suppressed Cataplexy in NT1 Mice
Wakefulness Latency to Cataplexy Maximal effect Maximal effect ORX750 (mg/kg, p.o.) ORX750 Increased Wakefulness and Suppressed Cataplexy in NT1 Mice NT1 is Narcolepsy Type 1. % of Time Awake refers to time spent awake in the first 3 hours after oral dosing. ORX750 preclinical data presentation at W
Slide 23: ORX750 Increased Wakefulness in Wild Type Mice
ORX750 Increased Wakefulness in Wild Type (WT) MicePRECLINICAL DATA 23 In WT mice (ie: orexin system is intact and functional), wake time increased at ≥ 1 mg/kg (lowest dose tested) Data collected using PiezoSleep, in which wakefulness readouts based on movement & breath rate highly correlate with E
Slide 24: ORX750 First-in-Human Healthy Volunteer PoC Study
24 IND OPEN ORX750 First-in-Human Healthy Volunteer (HV) PoC Study Phase 1 clinical study of ORX750: Evaluate the safety, tolerability and pharmacokinetics (PK) of single-ascending and multiple-ascending doses in healthy adult subjects In parallel A cross-over PoC portion of the study to assess phar
Slide 25: SAD Combined with HV Acute Sleep-Deprivation PoC Study
SAD Combined with HV Acutely Sleep-Deprivation PoC Study ORX750 Placebo Placebo ORX750 Washout MWT and KSSMWT and KSS N=12 HVs per cohort, randomized to ORX750 (N=9) or placebo (N=3) Dose escalate based on review of data from each cohort N≥10 HVs per cohort from SAD 1:1 randomization ORX750 Placebo
Slide 26: ORX750 Clinical PoC data expected in 2H of 2024
ORX750 Clinical PoC data in sleep-deprived healthy volunteers expected in 2H of 2024 26
Slide 27: Potential Multi-Billion-Dollar Market Opportunities
27 Narcolepsy Type 1 Narcolepsy Type 2 Idiopathic hypersomnia Excessive daytime sleepiness (EDS) in common disorders Potential Multi-Billion-Dollar Market Opportunities ORX750 & Follow-Up Orexin Agonists Evaluate Pharma Analyst Consensus for 2023 and UpToDate.
Slide 28: LockBody Technology Platform
28 Hemophilia Program LockBody Technology Platform Orexin Agonist Program
Slide 29: LockBody Technology Platform aims to redefine immuno-oncology treatment
29 LockBody Technology Platform aims to redefine immuno-oncology treatment Novel pharmacology combining tumor enrichment with activation of effector function Designed as single agent systemic treatment Potential wide therapeutic index1 LB101 is an investigational agent that has not been approved by
Slide 30: LockBody LB101 Locked Configuration
Locked Configuration MOA LockBody LB101 Conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody 30
Slide 31: LockBody LB101 Unlocked Configuration
Unlocked Configuration LockBody LB101 Conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody MOA 31
Slide 32: Significant Tumor Regression Observed In-Vivo with LB101
Significant Tumor Regression Observed In-Vivo with LB101 Source: In vivo- 5 mg/kg of atezolizumab is equivalent to 8.5 mg/kg of LB101. Data presented at ASCO in June 2022. https://investors.centessa.com/static-files/2f9bffb4-97a6-4320-8885- 70f12aa4d036. MC38 hPD-L1+ syngeneic model in mouse. Triang
Slide 33: Well Tolerated in Non-Human Primates with LB101 Doses up to 50mg/kg
Observed to be Well Tolerated in Non-Human Primates (NHPs) with LB101 Doses up to 50mg/kg Source: In-vivo- LB101 delivered IV at 5, 20, 50mg/kg (q7d x 4) in non-human primates. No anemia/ thrombocytopenia No weight loss No change in red blood cell or hemoglobin 33 PRECLINICAL DATA
Slide 34: Dosing subjects in ongoing Phase 1/2a trial of LB101
Dosing subjects in ongoing Phase 1/2a first-in-human clinical trial of LB101 34
Slide 35: 2024 Driving Momentum
35 2024 Driving Momentum ANTICIPATED MILESTONES LOCKBODY TECHNOLOGY PLATFORM LB101 Phase 1/2 study ongoing OREXIN AGONIST PROGRAM ORX750 Clinical PoC data in healthy volunteers expected in 2H of 2024 HEMOPHILIA PROGRAM SerpinPC Registrational study interim analysis expected in 2024
Slide 36: Discovering and developing medicines that are transformational for patients
Discovering and developing medicines that are transformational for patients 36 Multiple potential blockbuster assets Ongoing momentum in 2024 with clinical milestones anticipated across our most advanced programs Strong balance sheet OUR MISSION
Slide 37: Centessa Pharmaceuticals
>< CENTESSA PHARMACEUTICALS
Centessa Pharmaceuticals — Investor Presentation (April 2024) on 6ix